In vitro models for the determination of drug absorption and a prediction of dissolution/absorption relationships;Modelos in vitro para determinação da absorção de fármacos e previsão da relação dissoluçã o/absorção

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 43, Issue 4, 2007, Pages 515-527

  De Souza, Jacqueline ^a,d   Freitas, Zaida Maria F ^b   Storpirtis, Sílvia ^c  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Laboratório de Controle de Qualidade   (Brazil)

Author keywords

Caco 2 cell; Drug dissolution test; Drug oral absorption; Drug permeability; In vitro models

Indexed keywords

ACETYLSALICYLIC ACID; ALBENDAZOLE; ATENOLOL; CHLORPHENIRAMINE MALEATE; CIMETIDINE; COUMARIN; DEXAMETHASONE; DILTIAZEM; DISOPYRAMIDE; ENOXACIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LEVOFLOXACIN; MANNITOL; METOPROLOL TARTRATE; RANITIDINE; THEOPHYLLINE;

ANIMAL CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG INDUSTRY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; NONHUMAN; REVIEW;

EID: 42149166134     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-93322007000400004     Document Type: Review

References (81)

1. AMIDON, G.L.; LENNERNÄS, H.; SHAH, V.P.; CRISON, J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., v.12, n.3, p.413-420, 1995.
2. ARTURSSON, P.; BORCHARD, R.T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res., v.14, n.12, p.1655-1658, 1997.
3. ARTURSSON, P.; MAGNUSSON, C. Epithelial transport of drug in cell culture. II: Effect of extracellular calcium concentration on paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J. Pharm. Sci., v.79, n.7, p.595-600, 1990.
4. ASADA, H.; DOUEN, T.; WAKI, M.; ADACHI, S.; FUJITA, T.; YAMAMOTO, A.; MURANISHI, S. Absorption characteristics of chemical modified-insulin derivatives with various fatty acids in the small and large intestine. J. Pharm. Sci., v.84, p.682-687, 1995.
5. ATISOOK, K.; CARLSON, S.; MADARA, J.L. Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia. Am. J. Physiol., v.258, p. c77-c85, 1990.
6. AUNGST, B.; SHEN, D.D. Gastrointestinal absorption of toxic agents. In: ROZMAN, K.; HANNINEN, O. (Eds.), gastrointestinal toxicology. Elsevier, Amsterdam, 1986. p 29-56.
7. AULTON, M.E. Pharmaceutics: the science of dosage form design. New York: Churchil Livingstone, 1996. 734p.
8. BALAN, G.; TIMMINS, P.; GREENE, D.S.; MARATHE, P.H. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J. Pharm. Sci., v.90, p.1176-1185, 2001.
9. BALIMANE, P.V.; CHONG, S.; MORRISON, R.A. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods, v.44, p. 301-312, 2000.
10. BANAKAR, U.V. Pharmaceutical dissolution testing. New York, Marcel Dekker, 1992. 437p.
11. BARTHE, L.; WOODLEY, J.F.; KENWORTHY, S.; HOUIN, G. An improved everted gut sac as a simple and accurate technique measure paracellular transport across the small intestine. Eur. J. Drug Metab. Pharmacokinet., v.23, n.2, p.313-323, 1998.
12. BENET, L.Z.; CUMMINS, C.L.; WU, C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., v.277, p.3-9, 2004.
13. BOCK-HENNIG B.S.; KÖHLE C.; NILL K.; BOCK, K.W. Influence of t-buthylhydroquinone and b-naphythoflavone on formation and transport of 4-methylumbelliferone glucuronide in Caco-2/TC-7 cell monolayers. Biochem. Pharmacol., v.63, p.123-128, 2002.
14. BRASIL. RE no 482, de 19 de março de 2002. "Guia para estudos de correlação in vitro in vivo (CIVIV)". Via Internet, no endereço eletrônico. Disponível em http://e-legis.bvs.br/ leisref/public/showAct.php?id=1237&word=. Acesso em 10 jun 2005.
15. ÇELIK, M. The past, present, and future of tableting technology. Drug Develop. Ind. Pharm., v.22, n.1, p.1-10, 1996.
16. CHARMAN, W.N.; PORTER, C.J.H.; MITHANI, S.; DRESSMAN, J.B. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J. Pharm. Sci., v.86, n.3, p.269-279, 1997.
17. CHATURVEDI, P.R.; DECKER, C.J.; ODINECS, A. Prediction of pharmacokinetics properties using experimental approaches during early drug discovery. Curr. Opin. Chem. Biol., v. 5, p. 452-463, 2001.
18. CHEN, Y; PING Q.; GUO, J.; WENLI, L.; GAO, J. The absorption behavior of cyclosporin A lecithin vesicles in rat intestinal tissue. Int. J. Pharm., v. 261, p.21-26, 2003.
19. CHONG, S.; DANDO, S.; SOUCEK, K.; MORRISON, R. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for pe0ptide like drugs absorbed via the dipeptide transporter system. Pharm. Res., v.13, p.120-123, 1996.
20. CHONG, S.; DANDO, S.; MORRISON, R. Evaluation of Biocat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as na absorption screening model with improved productivity. Pharm. Res., v.14, p.1835-1837, 1997.
21. CONCIGLIERI, V.O.; STORPIRITIS, S. Bioequivalência de medicamentos: objetivos, parâmetros farmacocinéticos, delineamento experimental e critérios de avaliação. Rev. Bras. Cienc. Farm., São Paulo, v.36, p.13-21, 2000.
22. COOK, T.J.; SHENOY, S.S. Intestinal permeability of chlropyrifos using the single-pass intestinal perfusion method in the rat. Toxicol., v.184, p.125-133, 2003.
23. COX, D.C.; DOUGLAS, C.C.; FURMAN, W.B.; KIRCHHOEFER, R.D.; MYRICK, J.W. Guidelines for dissolution testing. Pharm. Technol., New York, v.2, p.41-53, 1978.
24. CUTLER, D.J.; BEYSSAC, E.; AIACHE, J.M. Level B and C in vivo/in vitro correlations: statistical considerations. Int. J. Pharm., v.158, p.185-193, 1997.
25. DESESSO, J.M.; JACOBSON, C.F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol., v.39, p.209-228, 2001.
26. DOKOUMETZIDIS, A.; MACHERAS, P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int. J. Pharm., v. 321, p. 1-11, 2006.
27. DRESSMAN, J.B.; AMIDON, G.L.; FLEISHER, D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci., v. 74, p. 598-599, 1985.
28. DRESSMAN, J.B.; AMIDON, G.L.; REPPAS, C.; SHAH, V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res., v. 15, n.1, 1998.
29. DUNE, A.; DEVANE, J.; O'HARA, T. The relationship between in vitro drug dissolution and in vivo absorption. Statistician, v.48, p.125-133, 1999.
30. EDDINGTON, N.D.; MARROUM, P.; UPPOOR, R.; HUSSAIN, A.; AUGSBURGER, L. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm. Res., v.15, p.466-473, 1998.
31. FARMACOPÉIA brasileira. 4.ed. São Paulo: Atheneu, 1988. pt.1.
32. GALVÄO, F. H. F.; WAITZBERG, D. L.; GONÇALVES, E. L.; SOARES, A. D. C. Permeabilidade intestinal de intestino delgado de ratos, preservados hipotermicamente com as soluções da Universidade de Wisconsin e Euro-Collins. Acta Cir. Bras., v. 8, p.54-8, 1993.
33. GERSHANIK, T.; HALTNER, E.; LEHR, C.-M.; BENITA, S. Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. Int. J. Pharm., v. 211, p. 29-36, 2000.
34. GINSKI, J.M.; POLLI, J.E. Prediction of dissolution-absorption relationships from a dissolution/ Caco-2 system. Int. J. Pharm., v. 177, p. 117-125, 1999.
35. GINSKI, J.M.; TANEJA, R.; POLLI, J.E. Prediction of dissolution- absorption relationships from a continuous dissolution/Caco-2 system. AAPS Pharm. Sci., v.1, n. 3, p. 1-12, 1999.
36. GRASS, G; SWEETANA, S. A correlation for permeabilities of passively transported compounds in monkey and rabbit jejunum. Pharm. Res., v.6, p. 857-862, 1989.
37. GRES M.; JULIAN B.; BOURRIE M.; ROQUES, C.; BERGER, M.; BOULENC, X.; BERGER, Y.; FABRE, G.; Correlation between oral drug absorption in human, and apparent drug permeability in TC-7cells, a human epithelial intestinal cell line: comparison with the parenteral Caco-2 cell line. Pharm. Res., v. 15, p. 726-733, 1998.
38. GRUNDY, J.S.; ANDERSON, K.E.; ROGERS, J.A.; FOSTER, R.T. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. description of a two phase in vitro dissolution test. J. Control. Release, v. 48, p. 1-8, 1997.
39. GUIDANCE for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on biopharmaceutics classification system. Rockville: FDA. 2000. 13p.
40. HE, X.; SUGAWARA, M.; KOBAYASHI, M.; TAKEKUMA, Y.; MIYAZAKI, K. Na in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs. Int. J. Pharm., v. 263, p. 35-44, 2003.
41. HITZ, J. The absorption window: fact or fiction? Pharm. Int., p. 175-178, 1984.
42. HOSSAIN, M.; ABRAMOWITZ, W.; WATROUS, B.J.; SZPUNAR, G.J.; AYREES, J.W. Gastrointestinal transit of nondisintegration, nonerodible oral dosage forms in pigs. Pharm. Res., v. 7, p. 1163-1166, 1990.
43. HORIE, K.; TANG, F.; BORCHARDT, R.T. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm. Res., v.20, p. 161-167, 2003.
44. IRVINE, J.D.; TAKAHASHI, L.; LOCKHART, K.; CHEONG, J.; TOLAN, J.W.; SELICK, H.E.; GROVE, J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci., v. 88, p. 28-33, 1999.
45. JONG, J.C.; WILLEMS, P.H.G.M.; HEUVEL, L.P.W.J.V.D.; KNOERS, N.V.A.M.; BINDELS, R.J.M. Function expression of the human thiazide-sensitive NaCl cotransporter in Madin-Darby Canine Kidney Cells. J. Am. Soc. Nephrol., v. 14, p. 2428-2435, 2003.
46. KARASOV, W.H.; DARKEN, B.W.; BOTTUM, M.C. Dietary regulation of intestinal ascorbate uptake in guinea pigs. Am. J. Physiol., v. 260, p. G108-G118, 1991.
47. KASSIN, N.A.; WHITEHOUSE, M.; RAMACHANDRAN, C.; BERMEJO, M.; LENNERNAS, H.; HUSSAIN, A.S.; JUNGINGER, H.E; STAVICHANSKY, S.A.; MIDHA, K.K.; SHAH, V.P.; AMIDON, G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm., v. 1, p. 85-96, 2003.
48. KATSURA, T.; INUI, K. Intestinal absorption of drug mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokin., v.18, n.1, p. 1-15, 2003.
49. KATORI, N.; AOYAGI, N.; TERAO, T. Estimation of agitation intensity in the GI tact in humans and dogs based on in vitro/in vivo correlation. Pharm. Res., v. 12, n. 2, p. 237-243, 1995.
50. KHAN, M.Z.I. dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int. J. Pharm., v. 140, p. 131-143, 1996.
51. KOBAYASHI, M.; SADA, N.; SUGAWARA, M.; ISEKI, K.; MIYAZAKI, K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int. J. Pharm., v. 221, p. 87-94, 2001.
52. LABOISSE, C.L.; JARRY, A.; BOU-HANNA, C.; MELIN, D.; VALLETTE, G. Intestinal cell culture models. Eur. J. Pharm. Sci., v. 2, p. 32-38, 1994.
53. LENTZ, K.A.; HAYASHI, J.; LUCISANO, L.J.; POLLI, J.E. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and a application to the biopharmaceutics classification system. Int. J. Pharm., v. 200, p. 41-51, 2000.
54. LUO, F.R.; PARANJPE, P.V.; GUO, A.; RUBIN, E.; SINKO, P. transport of irinotecan in Caco-2 cells and MDCK II cells over expressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab. Dispos., v. 30, p. 763-70, 2002.
55. MACHERAS, P.; ARGYRAKIS, P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm. Res., v. 14, p. 842-847, 1997.
56. MAKHEY, V.D.; GUO, A.; NORRIS D.A.; H.U. P.; YAN, J., SINKO, P.J. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res., v. 15, p.1160-7, 1998.
57. MANADAS, R.; PINA, M.E.; VEIGA, F. A dissolução in vitro na previsã;o da absorção oral de fármacos em formas farmacêuticas de liberação modificada. Brazilian J. Pharm. Sci., v. 38, p. 375-400, 2002.
58. MARIAPPAN T.T.; SINGH S. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol Pharm., v.1, p.363-7, 2004.
59. MARQUES, M.R.C. Desenvolvimento e validação de métodos de dissolução para formas farmacêuticas sólidas orais. Rev. Analytica, n.1, p. 48-51, 2002.
60. MENON, R.M.; BARR, W.H. Comparison of ceftibuten transport across Caco-2 cells and rat jejunum mounted on modified Using chambers. Biopharm. Drug Dispos., v. 24, p. 299-308, 2003.
61. NEULROFF, S.; UNGELL, A.L.; ZAMORA, I.; ARTUSSON, P. Ph-dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci., v. 25, p. 211-220, 2005.
62. PAPPENHEIMER, J.R.; REISS, K.Z. 1987. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J. Memb. Biol., v. 100, p. 123-136, 1987.
63. PIETZONKA, P.; WALTER, E.; DUDA-JOHNER, S.; LANGGUTH, P.; MERKLE, H.P. Compromised integrity of excised porcine intestinal epithelium obtained from the abattoir effects the outcome of in vitro particle uptake studies. Eur. J. Pharm. Sci., v. 15, p. 39-47, 2002.
64. POLLI, J.E.; CRISON, J.R.; AMIDON, G.L. Novel approach to the analysis of in vitro-in vivo relationships. J. Pharm. Sci., v. 85, p. 753-761, 1996.
65. PUTNAM, W.S.; PAN, L.; TSUTSUI, K.; TAKAHASHI, L.; BENET, L.Z. Comparison of bidirectional cephalexin transport across MDCK and Caco-2 cell monolayers: Interactions with peptide transporters. Pharm. Res., v.19, p. 27-33, 2002
66. RAO, B.S.; SESHASAYANA, A., SARADHI, S.V.P.; KUMAR, N.R.; NARAYAN, C.P.S.; MURTHY, K.V.R. Correlation of "in vitro" release and "in vivo" absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads. Int. J. Pharm., v. 230, p. 1-9, 2001.
67. ROUGE, N.; BURI, P.; DOELKER, E. Drug absorption sites in the gastrintestinal tract and dosage forms for site-specific delivery. Int. J. Pharm., v. 136, p. 117-139, 1996.
68. ROWLAND, R.N. ; WOODLEY, J.F. The uptake of distearoylphosphatidylcholine/cholesterol liposomes by rat intestinal sac in vitro. Biochim. Biophys. Acta, v. 673, p. 217-223, 1981.
69. RUBAS, W.; JEZYK, N.; GRASS, G.M. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm. Res., v. 10, p. 113-118, 1993.
70. SANTOS, C.A.; JACOB, J.S.; HETZOG, B.A.; FREEDMAN, B.D.; PRESS, D.L.; HARNPICHARNCHAI, P.; MATHIOWITZ, E. Correlation of two bioadhesion assays: The everted sac technique and the CAHN microbalance. J. Control. Rel., v. 61, p. 113-122, 1999.
71. SATHE, P.M.; TSONG, Y.; SHAH, V.P. In-vitro dissolution profile comparison: Statistic and analysis, model dependent approach. Pharm. Res., v. 13, p. 1799-1803, 1996.
72. SATO, K.; SUGIBAYASHI, K.; MORIMOTO, Y. Species differences in percutaneous adsorption of nicorandil. J. Pharm. Sci., v.80, p. 104-107, 1991.
73. SKELLY, J.P.; AMIDON, G.L.; BARR, W.H.; BENET, L.Z.; CARTER, J.E.; ROBINSON, J.R.; SHAH, V.P.; YACOBI, A. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm. Res., v. 7, p. 975-982, 1990.
74. STORPIRTIS, S.; CONSIGLIERI, O.V. Biodisponibilidade e bioequivalência de medicamentos: Aspectos fundamentais para o planejamento e execução de estudos. Rev. Bras. Cienc. Farm., v. 31, p. 63-70, 1995.
75. TAVELIN S.; MILOVIC V.; OCKLIND G.; OLSSON S.; ARTURSSON P. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J. Pharmacol. Exper. Ther., v. 290, p. 1212-1221, 1998.
76. TAVELIN S.; TAIPALENSUU, J.; SÖDERBERG, L.; MORRISON, R.; CHONG, S.; ARTURSSON P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res., v. 20, p. 397-405, 2003a.
77. TAVELIN, S.; TAIPALENSUU, J.; HALLBÖÖK, F.; VELLONEN, K-S.; MOORE, V.; ARTURSSON P. Na improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharm. Res., v. 20, p. 373-381, 2003b.
78. UNITED States Pharmacopeia: USP 29: The National Formulary: NF 24. Rockville: United States Pharmacopeial Convention, 2005. p.1064-1065, 1961-1963.
79. UPPOOR, V.R.S. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Rel., v. 72, p. 127-132, 2001.
80. WEGMANN, M.; NÜSING, R.M. Prostaglandin E2 stimulates sodium reabsorption in MDCK C7 cells, a renal collection duct principal cell model. Prostaglandins, Leukot. Essent. Fat. Acids, v. 69, p. 315-322, 2003.
81. WERLE M; HOFFER M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release., v. 111, p. 41-6, 2006.